Clinical Trials
14 trialsNCT06624644 2026-04-22
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT02278887 2025-03-10
TIL
The Netherlands Cancer Institute
Phase 3 Completed
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT04879654 2024-03-05
SNMM
Eye & ENT Hospital of Fudan University
Phase 2 Unknown
NCT02431572 2020-04-28
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Massachusetts General Hospital
Phase NA Completed
NCT03917069 2019-04-17
Nab-PCE vs PC for MM After Failure of Anti-PD-1
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01245062 2018-04-05
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
GlaxoSmithKline
Phase 3 Completed
NCT00707161 2017-03-31
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
University of Utah
Phase 2 Terminated
NCT00003715 2015-12-03
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
AVAX Technologies
Phase 2 Terminated
NCT01709162 2015-11-30
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Terminated
NCT00070642 2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2 Completed
NCT00041808 2005-06-24
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx
Phase 1/2 Completed